Background: The promising results of fludarabine (FLU) in chronic lymphocytic leukemia have prompted its extensive evaluation in low-grade non-Hodgkin's lymphoma (LG-NHL). Its different mechanisms of action make FLU an attractive partner for combination with other cytostatic agents.
Introduction
From a therapeutic standpoint, low-grade non-Hodgkin's lymphoma (LG-NHL) is a very controversial disease [1] [2] [3] [4] . Standard regimens including an alkylating agent have proved to be only palliative treatments, with a median survival of 6-8 years, and aggressive regimens including anthracyclines have not improved these results. The use of high-dose therapy followed by autologous hematopoietic rescue is being investigated; prolonged disease-free survival has been described although survival curves show no plateau and it is unclear whether any of the patients can be considered cured.
In patients who develop resistance to conventional drugs or who relapse or progress to a higher-grade malignancy, the probability of an effective therapeutic approach may become problematic.
New approaches include alternative biotechnological treatments such as immunotoxin therapy and radioimmunoconjugate therapy [5, 6] , and new drugs. Among the new agents, two purine analogs, fludarabine (FLU) and 2-chlorodeoxyadenosine (2-CdA), have been used extensively in previously treated LG-NHL patients [7] [8] [9] [10] [11] [12] [13] [14] , producing responses, albeit mostly partial ones, in 50%-60% of patients.
Recently, we and other groups conducted preliminary trials involving a combination of conventional cytotoxic drugs with FLU in order to enhance the antineoplastic activity of the latter [15] [16] [17] [18] [19] [20] . On the basis of preclinical experiments suggesting a synergistic activity of FLU when combined with mitoxantrone (because of inhibition of DNA repair), we and other investigators [15, 17, 18] tested a regimen containing FLU, mitoxantrone, and corticosteroids in relapsed/refractory LG-NHL patients; a 70%-80% response rate was obtained with a higher fraction of complete responders.
Following the encouraging data of these studies, we have now completed a phase II trial with FLU, mitoxantrone, and prednisone (FMP regimen) in 48 previously treated patients with LG-NHL, on which we report herein.
Patients and methods
From November 1993 to November 1995, 48 previously treated patients with LG-NHL entered this phase II study. The criteria for entry included: histologic diagnosis of LG-NHL according to the updated Kiel classification [21] with histology reassessment before study entry; advanced (bulky stage II or stages 1II-IV) disease as outlined by the Ann Arbor Conference [22] ; the presence of measurable disease; normal hepatic, renal, and cardiac function; radiation and chemotherapy had to have been discontinued at least six weeks before the start of treatment. Informed consent was obtained from all patients in accordance with the ethical policy of the institute.
Staging evaluation included bone marrow biopsy (including immunohistochemical analysis), immunophenotypic profile of the peripheral blood, and hematologic and chemical survey, in addition to chest radiograms, abdominal ultrasonography and computerized tomography of the chest and abdomen in all patients. Lactate dehydrogenase (LDH) and serum (32-microglobulin ((32-M) were determined in all patients
The FMP regimen schedule was as follows: FLU 25 mg/m 2 i.v. on days one to three, mitoxantrone 10 mg/m 2 i.v. on day one, and prednisone 40 mg given orally on days one to five (as already published) [17] . FLU was supplied by Schering S.p.A. (Milan, Italy). Courses were given at three-week intervals for a maximum of six cycles. All patients received Pneumocystis carinii prophylaxis with cotrimoxazole (two consecutive days per week) during the entire course of treatment.
Patients were restaged after completion of six cycles; clinical and pathologic evaluations were made by repeating radiographic investigations and bone marrow biopsy if previous results were positive.
Patients' characteristics
Of the 48 patients with LG-NHL, 26 were male and 22 female The median age was 54 years (range 39 to 70 years). Eight patients had stage II, 14 stage III, and 26 stage IV disease; systemic symptoms were present in 15 patients. The time from the initial diagnosis of LG-NHL to the start of the FMP regimen ranged from 20 to 58 months (median 34 months).
Prior therapy included doxorubicin in all but two of the patients; ten patients received a previous regimen including mitoxantrone. None of the 48 patients had received prior purine analog-containing regimens. All of the patients had recurrent, relapsed disease and none presented resistant disease. By histology, 22 patients had centroblastic/ centrocytic follicular lymphoma, eight patients centroblastic/centrocytic follicular and diffuse lymphoma, and 18 immunocytoma lymphoplasmacytoid lymphoma. All these patients had previously received one (12 pts), two (15 pts), or three or more (21 pts) chemotherapy regimens.
of 83%. The remaining eight (17%) patients did not respond to the therapy. Response to the FMP regimen was rapid and became evident in all responding patients following two to three courses of treatment. The responses with respect to different clinical and biological features are summarized in Table 1 .
The likelihood of response only partially correlated with the number of prior chemotherapeutic regimens (Table 1 ). In fact, among the 12 patients who had received only one previous chemotherapy regimen, the overall response rate was 91% (7 CR (58%) and 4 PR (33%)), a figure only slightly higher than the 87% overall response rate (7 CR (47%) and 6 PR (40%)) recorded in the 15 patients who had undergone two previous regimens. On the other hand, among the 21 patients who had received three or more previous regimens, there was a significantly lower number of CR (3 (14%); P = 0.006) and 13 PR (62%).
Of the 17 patients who obtained CR, 10 are still in remission after 5 to 23 months; the median duration of CR was 18 months (range, 5 to 23 months). Ten of the 23 partial responders remained in PR for a median duration of 10 months (range, 4 to 18 months); 4 of 23 died, one of infection and three of progression of disease.
The overall survival ( Figure 1 ) at 33 months was 67%. Figure 2 shows the probability of relapse-free survival
Response criteria
Complete response (CR) was defined as a complete disappearance of signs and lymphoma-associated symptoms (including the contingent monoclonal IgM peak) that was maintained for at least six weeks. A reduction by at least 50% of known disease (including the contingent monoclonal IgM peak) with disappearance of systemic manifestations for a duration of at least six weeks was defined as partial response (PR).
The maximum planned treatment duration was six cycles Patients with progressive disease were considered as having no response and received no further therapy.
The survival curve was measured from entry into the protocol until death; the relapse-free interval was calculated from the date of response until relapse or death. Survival and relapse-free survival curves were calculated according to the method of Kaplan and Meier [23] . Standard Eastern Cooperative Oncology Group toxicity criteria were used [24] .
Statistical analysis
Comparisons among groups were performed by the Wilcoxon twosample test, and the differences were considered significant at /'-values of less than 0.05. Clinical and laboratory parameters were combined and entered into a multivariate logistic regression model to determine the most appropriate combination of covanates for predicting achievement of a CR [25] .
Results

Response
Of the 48 patients studied, 17 (35%) fulfilled the criteria for CR and 23 (48%) for PR, for an overall response rate projected at 33 months (median 15 months): 32% for CR and 18% for PR, respectively. The median follow-up time of surviving patients was 21 months.
With respect to histology, the overall response rate for the immunocytoma lymphoplasmacytoid subtype was 83% with 55% CR, whereas the follicular subtypes presented an overall response rate of 83% with a CR rate of 23% (P -0.02 for CR rate) ( Table 1) . No relationship between response and age, sex, and LDH levels, P2-M levels was observed.
With regard to disease stage, we observed CR in five (62.5%) stage II patients, seven (50%) stage III patients, and five (19%) stage IV patients (Table 2 ) (stages II-III vs. stage IV, P = 0.01).
The following parameters were also examined in multivariate analysis in order to evaluate their influence on CR rate: age (^ 50 vs. > 50 years), sex, stage (II-III vs. IV), histology (follicular vs. immunocytoma), number of previous regimens (1-2 vs. >3), LDH and (32-M levels. Of these, the presence of advanced disease (P = 0.001), number of previous regimens (P -0.005), and follicular subtype (P = 0.01) predicted an increased risk of treatment failure.
According to International Prognostic Index criteria [26] , only one of the six patients with high or highintermediate risk achieved CR. In the 15 low-risk patients, 7 CR (47%) were documented, and among patients with low-intermediate risk, 10 of 27 CR (37%) were recorded (Table 2) . This difference was statistically significant (P -0.05).
Toxic effects
The FMP regimen was well tolerated in general, and all of the responder patients completed therapy. Myelosuppression and infections were the major side effects. With regard to hematologic toxicity, neutropenia was observed in 24 (50%) patients, of whom eight (17%) had grades 3 or 4. Thrombocytopenia, which was observed in 18 (37.5%) patients, was much less severe (grades 1 and 2).
Fifteen (6%) of a total of 259 courses were temporarily postponed for one week because of neutropenia and/or thombocytopenia, but no trend toward cumulative myelosuppression was observed; no dose reductions were applied and growth factors were not required.
The other major side effects were represented by infections and febrile episodes. Fever of undetermined origin occurred in eight (17%) patients. Of the 11 (23%) patients who experienced infections, four required symptomatic treatment or oral antibiotics, and five required parenteral antibiotics and/or hospitalization. As to opportunistic infections, Pneumocystis carinii pneumonia was not recorded. Two cases of dermatomal herpes zoster were observed.
All major infections involved the respiratory tract or sinuses. The one death was attributed to staphylococcal septicemia in a partial responder one month after completion of the FMP regimen. No direct correlation was observed between the intensity of neutropenia status after treatment and the incidence of febrile episodes.
Additional non-hematologic side effects were minimal and represented by nausea-vomiting in three patients (all grade 1), renal toxicity in two patients (grade 1), and local skin reactions in three patients (one grade 1 and two grade 2). No patient presented alopecia or neurotoxicity; no cardiac side effects (monitored with echocardiogram before and after the courses) were observed.
Discussion
Of the 48 relapsed/refractory LG-NHL patients evaluated in this study for response to and toxic effects of the FMP regimen, we obtained an encouraging overall response rate of 83% with a CR rate of 35%. FMP was a relatively well-tolerated regimen with frequent mild toxic reactions characterized mainly by myelosuppression and infections.
LG-NHL continues to be a difficult disease to treat and cure in the majority of patients. In fact, the treatment options range from the classic 'watch and wait' approach [27, 28] to high-dose chemotherapy plus radiotherapy with rescue of bone marrow or peripheral blood stem cells [29] [30] [31] , as well as conventional chemotherapeutic COP-like and CHOP-like regimens [32, 33] . Despite the indolent outcome and/or positive response to alkylating agents, LG-NHL often becomes resistant to these drugs or progresses more aggressively.
New drugs are needed for the treatment of this disease, and the relatively recent advent of purine analogs represents an effective alternative. In particular, FLU has been shown to produce sustained remission in LG-NHL either alone [7] [8] [9] [10] [11] [12] [13] [14] or in combination with other drugs [15] [16] [17] [18] [19] [20] . In particular, mitoxantrone, which is one of the most effective single agents in the treatment of recurrent LG-NHL [34, 35] , has so far proved to be the best conventional agent to utilize in combination with FLU [15] [16] [17] [18] .
FLU's activity in slowly proliferating cells is probably mainly related to the induction of apoptosis [36, 37] . Preliminary experiences have suggested a synergistic activity of FLU combined with mitoxantrone, through the inhibition of DNA repair [15] .
The results of our study with the FMP regimen confirm those obtained by McLaughlin [15, 18] and Pott [16] , and our own preliminary data [17] , which also showed higher overall response rates and higher percentages of CR than those of FLU alone. Furthermore, the FMP regimen seems to be more active in patients submitted to only one or two previous regimens of chemotherapy than in heavily pretreated patients {P = 0.006). It also seems to be more effective in stages II-111 than in stage IV {P -0.01). As regards histology, FMP is effective in all three subtypes of LG-NHL, although it is noteworthy that in immunocytoma patients the CR rate was significantly higher than in follicular subtype (P -0.02).
The toxicity of the FMP regimen was moderate. The most clinically significant effects were neutropenia, occurring in 24 (50%) patients, but cases of grade 4 toxicity were rare and reversible. Infections occurred in 11 patients. No cases of opportunistic infection were seen utilizing the prophylaxis with cotrimoxazole in the protocol. It is known that the combination of FLU and corticosteroids can give rise to increased opportunistic infections in patients with chronic lymphocytic leukemia; however, in our LG-NHL patients, no such increase was observed.
These results confirm that FMP, a fludarabine/mitoxantrone-based regimen is effective in the treatment of patients with LG-NHL, particularly those with immunocytoma histology. In fact, this polychemotherapeutic regimen is associated with significantly higher overall response and CR rates than those obtained with FLU alone in relapsed and advanced LG-NHL patients (70%-80% and 20%-30% versus 40%-50% and 5%-10%, respectively).
Considering the minimal role of toxicity and the duration of response in advanced pretreated patients, these data encourage us to believe that the fludarabine/ mitoxantrone-based regimen could represent the best second-line treatment available for LG-NHL. In light of the poor results achieved by current first-line treatment options using conventional cytotoxic agents, and of the interesting data obtained with FLU alone in firstline treatment for LG-NHL [38] , we believe that FMP could be incorporated into a first-line approach for patients with LG-NHL. In fact, the preliminary data from our pilot study (data not published) and from the Keating group [39] confirm the significant role that this regimen can play in the first-line treatment of indolent lymphoma.
